伊立替康注射液致UGT1A1*28野生型患者重度骨髓抑制和腹泻1例

中国药物警戒 ›› 2018, Vol. 15 ›› Issue (12): 761-763.

伊立替康注射液致UGT1A1*28野生型患者重度骨髓抑制和腹泻1例

周秋云, 张宇, 张亮, 陆磊, 鲁涛

东南大学附属南京胸科医院,江苏南京 210029

收稿日期:2019-01-18 修回日期:2019-01-18 出版日期:2018-12-20 发布日期:2019-01-18
作者简介:周秋云,女,本科 ,副主任药师,临床药学。
基金资助:
江苏省奥赛康医院药学基金（A2017013）：UGT1A1、SLCO1B1基因多态性与伊立替康所致严重不良反应的相关性研究;南京市药学会常州四药基金(2016YX015)：SLCO1B1基因多态性与伊立替康在小细胞肺癌中疗效的相关性研究

One Case of Severe Myelosuppression and Diarrhea Induced by Irinotecan Injection in a UGT1A1*28 Wide-type Patient

ZHOU Qiuyun, ZHANG Yu, ZHANG Liang, LU Lei, LU Tao

Department of Pharmacy, Nanjing Chest Hospital, School of Medicine, Southeast University, Jiangsu Nanjing 210029, China

Received:2019-01-18 Revised:2019-01-18 Online:2018-12-20 Published:2019-01-18

摘要/Abstract

中图分类号:

R994.11

周秋云, 张宇, 张亮, 陆磊, 鲁涛. 伊立替康注射液致UGT1A1*28野生型患者重度骨髓抑制和腹泻1例[J]. 中国药物警戒, 2018, 15(12): 761-763.

ZHOU Qiuyun, ZHANG Yu, ZHANG Liang, LU Lei, LU Tao. One Case of Severe Myelosuppression and Diarrhea Induced by Irinotecan Injection in a UGT1A1*28 Wide-type Patient[J]. Chinese Journal of Pharmacovigilance, 2018, 15(12): 761-763.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/

https://zgywjj.magtechjournal.com/CN/Y2018/V15/I12/761

参考文献

[1] Zhou C F, Ma T, Su Y, et al.UGT1A1 gene polymorphisms and the toxicities of FOLFIRI in Chinese Han patients with gastroin-testinal cancer[J]. Anticancer Agents Med Chem, 2013, 13(2): 235-241.
[2] Zhang X G, Zhang X.Study on the development of the mechanism of action, prevention and treatment for irinotecan-induced diarrhea[J]. Chinese Journal of Pharmacovigilance, 2012, 9(9): 535-538.
[3] Di Paolo A, Bocci G, Polillo M,et al.Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity[J]. Curr Drug Metab, 2011, 12(10):932-943.
[4] Innocenti F, Undevia S D, Iyer L, et al.Genetic variants in the UDP–glucuronosyltransferase 1A1 gene predict the risk of severe neu-tropenia of irinotecan[J]. J Clin Oncol, 2004, 22(8): 1382-1388.
[5] Massacesi C, Terrazzino S, Marcucci F, et al.Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy[J]. Cancer, 2006, 106( 5): 1007-1016.
[6] Liu X L, Yang M D, Gao J.Relationship between UGT1A1 gene pol-ymorphisms and toxicity of irinotecan[J]. Chin Remedies&Clin, 2013, 13( 11): 1402-1404.
[7] Takahara N, Nakai Y, Isayama H, et al.Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer[J]. Cancer Chem Pharmacol, 2013, 71(1): 85-92.
[8] Harada T, Saito H, Karino F, et al.Clinical usefulness of testing for UDP glucuronosyltransferase 1 family,polypeptide A1 polymorp-hism prior to the nititation of irinotecan-based chemotherapy[J]. Mol Clin Oncol, 2014, 2(5): 737-743.
[9] Schulz C, Heinemann V, Schalhorn A, et al.UGT1A1 gene polymorphism Impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorecatal cancer[J]. World J Gastroenterol, 2009, 15(40): 5058-5066.
[10] Kehrer D, Sparreboom A, Verweijj, et al. Modualtion of irinotecan induced diarrhea by cotreatment with neomycin in cancer patients[J]. Clin Cancer Res, 2001, 7(5), 1136-1141.
[11] 刘建平,邢建民. 循证的药品不良反应评价方法[J]. 中国药物警戒, 2010, 17(1): 12-15.
[12] 范燕,汤韧,井春梅,等. 药学期刊药品不良反应案例报道论文的要点探讨[J].中国药物警戒, 2017, 1(2): 101-103.
[13] Cheng L, Li M,Hu J, et al.UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analrsis in Asians[J]. Cancer Chemother Pharmaco, 2014, 73(3), 5551-560l.
[14] Takano M, Kato M, Yoshikawa T, et al.Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination-chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study[J]. Oncology, 2009, 76(5): 315-321.
[15] Han J Y, Lim H S, Sin E S, et al.Influence of the organican iontransporting polypeptide 1B1(OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advancednon-small cell lung cancer[J], Lung Cancer, 2008, 59(1): 69-75.
[16] 张晓光,张侠. 25例伊立替康治疗晚期肠癌致不良反应的分析[J]. 中国药物警戒 , 2013, 10(3): 168-171.
[17] Nies A T, Niemi M, burk O, et al. Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of QATP1B3 and OATP2B1[J]. Genome Med, 2013, 5(1):1.
[18] Takane H, Miyata M, Burioka N, et al.Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLO1B1*15 Allele[J]. Ther Drug Monit, 2007, 29(5): 666-668.